Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.